Cemiplimab

Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research[1][2].

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) can increased the proportion of effector T cells in tumors and dLNs to reduce tumor growth by combined immunotherapy with REGN3767 in MC38.Ova tumor mice model[2]. Animal Model: Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells[2] Dosage: 10 mg/kg Administration: Intraperitoneal injection; five injections within 2 weeks Result: Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone. Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.

[1]. Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351.

[2]. Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062.